keyword
https://read.qxmd.com/read/38662980/toward-equitable-precision-oncology-monitoring-racial-and-ethnic-inclusion-in-genomics-and-clinical-trials
#1
JOURNAL ARTICLE
Jennyfer M García-Cárdenas, Alberto Indacochea, David Pesantez-Coronel, Martín Terán-Navas, Ana Aleaga, Isaac Armendáriz-Castillo, Lizbeth Peña Zúñiga, Carla Morán-Erazo, Erik Chávez-Vélez, Andy Pérez-Villa, Andrés López-Cortés, Santiago Guerrero
PURPOSE: Ethnic diversity in cancer research is crucial as race/ethnicity influences cancer incidence, survival, drug response, molecular pathways, and epigenetic phenomena. In 2018, we began a project to examine racial/ethnic diversity in cancer research, with a commitment to review these disparities every 4 years. This report is our second assessment, detailing the present state of racial/ethnic diversity in cancer genomics and clinical trials. METHODS: To study racial/ethnic inclusion in cancer genomics, we extracted ethnic records from all data sets available at cBioPortal (n = 125,128 patients) and cancer-related genome-wide association studies (n = 28,011,282 patients) between 2018 and 2022...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38658988/osimertinib-in-combination-with-anti-angiogenesis-therapy-presents-a-promising-option-for-osimertinib-resistant-non-small-cell-lung-cancer
#2
JOURNAL ARTICLE
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
BACKGROUND: Osimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients whereas drug resistance remains inevitable. Now we recognize that the interactions between the tumor and the tumor microenvironment (TME) also account for drug resistance. Therefore, we provide a new sight into post-osimertinib management, focusing on the alteration of TME. METHODS: We conducted a retrospective study on the prognosis of different treatments after osimertinib resistance...
April 24, 2024: BMC Medicine
https://read.qxmd.com/read/38657702/radon-and-lung-cancer-current-status-and-future-prospects
#3
REVIEW
Yan Liu, Yanqing Xu, Wei Xu, Zhengzhong He, Cong Fu, Fen Du
Beyond tobacco smoking, radon takes its place as the second most significant contributor to lung cancer, excluding hereditary and other biologically related factors. Radon and its byproducts play a pivotal role in exposing humans to elevated levels of natural radiation. Approximately 10-20% of lung cancer cases worldwide can be attributed to radon exposure, leading to between 3% and 20% of all lung cancer-related deaths. Nevertheless, a knowledge gap persists regarding the association between radon and lung cancer, impeding radon risk reduction initiatives globally...
April 22, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38648575/resilient-part-2-a-randomized-open-label-phase-iii-study-of-liposomal-irinotecan-versus-topotecan-in-adults-with-relapsed-small-cell-lung-cancer
#4
JOURNAL ARTICLE
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis Paz-Ares, Paul A Bunn
PURPOSE: The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS)...
April 22, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38646225/the-safety-and-effectiveness-of-bevacizumab-in-metastatic-colorectal-cancer-with-unresectable-metastases-a-real-life-study-from-the-south-of-morocco
#5
JOURNAL ARTICLE
Ghizlane Rais, Farah Boutaagount, Rania Mokfi, Meryem Maskrout, Soundous Bennour, Chaymae Senoussi, Fadoua Rais, Laila Lahlou
Background Colorectal cancer constitutes a significant public health challenge, despite remarkable strides made in the last two decades, particularly in the medical management of metastatic stages. Notable progress has been achieved through targeted therapies such as anti-epidermal growth factor receptors or anti-angiogenic antibodies, as well as advancements in surgical approaches for hepatic metastases. This study seeks to assess the efficacy and safety of bevacizumab plus chemotherapy in individuals with metastatic colorectal cancer...
March 2024: Curēus
https://read.qxmd.com/read/38645169/respiratory-viral-infection-promotes-the-awakening-and-outgrowth-of-dormant-metastatic-breast-cancer-cells-in-lungs
#6
Shi B Chia, Bryan J Johnson, Junxiao Hu, Roel Vermeulen, Marc Chadeau-Hyam, Fernando Guntoro, Hugh Montgomery, Meher Preethi Boorgula, Varsha Sreekanth, Andrew Goodspeed, Bennett Davenport, Felipe V Pereira, Vadym Zaberezhnyy, Wolfgang E Schleicher, Dexiang Gao, Andreia N Cadar, Michael Papanicolaou, Afshin Beheshti, Stephen B Baylin, James Costello, Jenna M Bartley, Thomas E Morrison, Julio A Aguirre-Ghiso, Mercedes Rincon, James DeGregori
Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy1 . Understanding the mechanisms that disrupt the quiescence of dormant disseminated cancer cells (DCC) is crucial for addressing metastatic progression. Infection with respiratory viruses (e.g. influenza or SARS-CoV-2) is common and triggers an inflammatory response locally and systemically2,3 . Here we show that influenza virus infection leads to loss of the pro-dormancy mesenchymal phenotype in breast DCC in the lung, causing DCC proliferation within days of infection, and a greater than 100-fold expansion of carcinoma cells into metastatic lesions within two weeks...
April 5, 2024: Research Square
https://read.qxmd.com/read/38644676/graphene-and-metal-organic-framework-hybrids-for-high-performance-sensors-for-lung-cancer-biomarker-detection-supported-by-machine-learning-augmentation
#7
JOURNAL ARTICLE
Anh Tuan Trong Tran, Kamrul Hassan, Tran Thanh Tung, Ashis Tripathy, Ashok Mondal, Dusan Losic
Conventional diagnostic methods for lung cancer, based on breath analysis using gas chromatography and mass spectrometry, have limitations for fast screening due to their limited availability, operational complexity, and high cost. As potential replacement, among several low-cost and portable methods, chemoresistive sensors for the detection of volatile organic compounds (VOCs) that represent biomarkers of lung cancer were explored as promising solutions, which unfortunately still face challenges. To address the key problems of these sensors, such as low sensitivity, high response time, and poor selectivity, this study presents the design of new chemoresistive sensors based on hybridised porous zeolitic imidazolate (ZIF-8) based metal-organic frameworks (MOFs) and laser-scribed graphene (LSG) structures, inspired by the architecture of the human lung...
April 22, 2024: Nanoscale
https://read.qxmd.com/read/38644287/-experts-consensus-on-transbronchial-diagnosis-localization-and-treatment-of-peripheral-pulmonary-nodules-guided-by-the-augmented-reality-optical-lung-navigation
#8
JOURNAL ARTICLE
(no author information available yet)
Lung cancer is the second most common malignancy with the highest mortality rate worldwide. In recent years, the rapid development of various bronchoscopic navigation techniques has provided conditions for the minimally invasive diagnosis and treatment of peripheral pulmonary nodules through the airway.Augmented reality optical lung navigation is a new technology that combined virtual bronchoscopy navigation (VBN) with augmented reality (AR) and optical navigation technology, which could assist bronchoscopist and has been widely applied in clinics...
April 23, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/38644242/-recurrence-pattern-of-pathological-complete-response-after-neoadjuvant-chemoradiotherapy-in-locally-advanced-rectal-cancer
#9
JOURNAL ARTICLE
Z G Sun, H Z Zhang
Patients with locally advanced rectal cancer who undergo neoadjuvant chemoradiotherapy may achieve pathological complete response (pCR). The incidence of recurrence is low among patients with pCR, there is still a lack of consensus on postoperative treatment and follow-up strategy. This review summarizes the recurrence patterns of patients with pCR, including distant metastasis rate, characteristics of distant metastasis time and location, local recurrence rate, and local recurrence time. The aim is to provide reference for the postoperative treatment and follow-up strategy of patients with pCR...
April 25, 2024: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38643197/enhanced-recovery-after-surgery-program-focusing-on-chest-tube-management-improves-surgical-recovery-after-video-assisted-thoracoscopic-surgery
#10
JOURNAL ARTICLE
Dan Yang, Xi Zheng
OBJECTIVE: Chest drainage is a standard procedure in thoracoscopic surgery for lung cancer. However, chest tube placement may deteriorate the ventilation capacity and increase difficulty of postoperative management of patients. The study investigated on the effects of enhanced recovery after surgery (ERAS) program focusing on chest tube management on surgical recovery of lung cancer patients. METHODS: The study population consisted of 60 patients undergoing video-assisted thoracoscopic surgery (VATS) after implementation of ERAS program and another group of 60 patients undergoing VATS before implementation of ERAS program...
April 20, 2024: Journal of Cardiothoracic Surgery
https://read.qxmd.com/read/38641349/association-of-metabolomics-with-pd-1-inhibitor-plus-chemotherapy-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer
#11
JOURNAL ARTICLE
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Baohui Han, Hua Zhong, Wei Nie, Xueyan Zhang
BACKGROUND: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment outcomes. Emerging evidence from various cancers suggests that early assessment of serum metabolites could serve as valuable biomarkers for predicting outcomes. This study aims to identify metabolites linked to treatment outcomes in patients with advanced NSCLC undergoing first-line or second-line therapy with programmed cell death 1 (PD-1) inhibitors plus chemotherapy...
April 18, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38640268/predicting-the-risk-of-lung-cancer-using-machine-learning-a-large-study-based-on-uk-biobank
#12
JOURNAL ARTICLE
Siqi Zhang, Liangwei Yang, Weiwen Xu, Yue Wang, Liyuan Han, Guofang Zhao, Ting Cai
In response to the high incidence and poor prognosis of lung cancer, this study tends to develop a generalizable lung-cancer prediction model by using machine learning to define high-risk groups and realize the early identification and prevention of lung cancer. We included 467,888 participants from UK Biobank, using lung cancer incidence as an outcome variable, including 49 previously known high-risk factors and less studied or unstudied predictors. We developed multivariate prediction models using multiple machine learning models, namely logistic regression, naïve Bayes, random forest, and extreme gradient boosting models...
April 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38638689/schwann-cells-in-the-normal-and-pathological-lung-microenvironment
#13
REVIEW
Michael R Shurin, Sarah E Wheeler, Galina V Shurin, Hua Zhong, Yan Zhou
The lungs are a key organ in the respiratory system. They are regulated by a complex network of nerves that control their development, structure, function, and response to various pathological stimuli. Accumulating evidence suggests the involvement of a neural mechanism in different pathophysiological conditions in the lungs and the development and progression of common respiratory diseases. Lung diseases are the chief source of death globally. For instance, lung cancer is the second most commonly diagnosed malignancy, after prostate cancer in men and breast cancer in women, and is the most lethal cancer worldwide...
2024: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/38638242/assessing-the-effectiveness-and-safety-of-lenvatinib-and-everolimus-in-advanced-renal-cell-carcinoma-insights-from-the-relieve-study-s-analysis-of-heavily-pretreated-patients
#14
JOURNAL ARTICLE
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
BACKGROUND: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. OBJECTIVES: The primary objective was to assess the effectiveness of the lenvatinib plus everolimus combination and the secondary objective was the toxicity profile of this combination. DESIGN: We conducted a longitudinal retrospective study examining mRCC patients pre-treated with one or more lines of therapy among different cancer centers in Italy...
2024: Therapeutic Advances in Urology
https://read.qxmd.com/read/38637357/clinical-difference-on-the-variants-and-co-mutation-in-a-chinese-cohort-with-alk-positive-advanced-non-small-cell-lung-cancer
#15
JOURNAL ARTICLE
Ying Fu, Qing Liu, Xiaohan Wang, Liangchao Sun, Xiao Han, Xue Meng
PURPOSE: Despite the generally favourable prognoses observed in patients with ALK-positive non-small cell lung cancer (NSCLC), there remains significant variability in clinical outcomes. The objective of this study is to enhance patient stratification by examining both the specific sites of gene fusion and the presence of co-occurring mutations. METHODS: We collected retrospective clinical and pathological data on ALK-positive patients with locally advanced or metastatic disease...
April 18, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38636827/a-serial-image-analysis-architecture-with-positron-emission-tomography-using-machine-learning-combined-for-the-detection-of-lung-cancer
#16
JOURNAL ARTICLE
S Guzmán Ortiz, R Hurtado Ortiz, A Jara Gavilanes, R Ávila Faican, B Parra Zambrano
INTRODUCTION AND OBJECTIVES: Lung cancer is the second type of cancer with the second highest incidence rate and the first with the highest mortality rate in the world. Machine learning through the analysis of imaging tests such as positron emission tomography/computed tomography (PET/CT) has become a fundamental tool for the early and accurate detection of cancer. The objective of this study was to propose an image analysis architecture (PET/CT) ordered in phases through the application of ensemble or combined machine learning methods for the early detection of lung cancer by analyzing PET/CT images...
April 16, 2024: Revista española de medicina nuclear e imagen molecular
https://read.qxmd.com/read/38635897/complex-bronchopleural-fistulas-a-case-report
#17
JOURNAL ARTICLE
Miaoying Cao, Jing Yi, Hongjie Bao, Jian Sun, Yefeng Chen
Bronchopleural fistula (BPF) is a potentially fatal complication and remains a surgical challenge. Concomitant problems, such as pulmonary infection and respiratory failure, are typically the main contributors to mortality from BPF because of improper contact between the bronchial and pleural cavity. We present the case of a 75-year-old male patient with a history of right upper lobe lung cancer resection who developed complex BPFs. Following appropriate antibiotic therapy and chest tube drainage, we treated the fistulas using endobronchial valve EBV placement and local argon gas spray stimulation...
April 2024: Journal of International Medical Research
https://read.qxmd.com/read/38635839/comorbidities-affecting-re-admission-and-survival-in-covid-19-application-of-joint-frailty-model
#18
JOURNAL ARTICLE
Akram Yazdani, Seyyed Ali Mozaffarpur, Pouyan Ebrahimi, Hoda Shirafkan, Hamed Mehdinejad
BACKGROUND: One of the common concerns of healthcare systems is the potential for re-admission of COVID-19 patients. In addition to adding costs to the healthcare system, re-admissions also endanger patient safety. Recognizing the factors that influence re-admission, can help provide appropriate and optimal health care. The aim of this study was to assess comorbidities that affect re-admission and survival in COVID-19 patients using a joint frailty model. METHODS: This historical cohort study was done using data of patients with COVID-19 who were re-hospitalized more than twice in a referral hospital in North of Iran...
2024: PloS One
https://read.qxmd.com/read/38630555/overcoming-osimertinib-resistance-with-akt-inhibition-in-egfrm-driven-non-small-cell-lung-cancer-with-pik3ca-pten-alterations
#19
JOURNAL ARTICLE
Ursula Grazini, Aleksandra Markovets, Lucy Ireland, Daniel O'Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J Martin, Ludovic Bigot, Luc Friboulet, Ryan Hartmaier, Maria Emanuela Cuomo, Simon T Barry, Paul D Smith, Nicolas Floc'h
PURPOSE: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) indicated for the treatment of EGFR mutated (EGFRm)-driven lung adenocarcinomas. Osimertinib significantly improves progression-free survival in first-line treated patients with EGFRm advanced NSCLC. Despite the durable disease control, the majority of patients receiving osimertinib eventually develop disease progression. EXPERIMENTAL DESIGN: ctDNA profiling analysis on-progression plasma samples from patients treated with osimertinib in both first (Phase 3, FLAURA trial) and second-line trials (Phase 3, AURA3 trial) revealed a high prevalence of PIK3CA/AKT/PTEN alterations...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38629016/mortality-audit-of-cancer-patients-in-the-department-of-medical-oncology-at-a-tertiary-cancer-care-centre-in-south-india
#20
JOURNAL ARTICLE
Akansha Choudhary, Linu A Jacob, Suresh Babu, Lokesh K N, Rudresha A H, Rajeev L K, Smitha Saldanha, Tarjina Begum
Considerable advances in the diagnosis and treatment of cancer have made a huge impact on morbidity and mortality from neoplastic diseases. However, cancer remains the leading cause of death across the world. This is a retrospective study carried out at a tertiary cancer care centre (Kidwai Memorial Institute of Oncology, Bangalore) in South India. Case records of all cancer patients who died while receiving inpatient treatment between January 2022 and December 2022 under the Department of Medical Oncology were reviewed and studied...
March 2024: Curēus
keyword
keyword
89876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.